Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioAtla (BCAB)
NASDAQ:BCAB
Holding BCAB?
Track your performance easily
BCAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.57 - $4.02
Previous Close$0.6
Volume1.49M
Average Volume (3M)1.11M
Market Cap
$34.91M
Enterprise Value-$20.36M
Total Cash (Recent Filing)$56.52M
Total Debt (Recent Filing)$1.25M
Price to Earnings (P/E)―
Beta3.77
Next Earnings
Mar 20, 2025EPS Estimate
-$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding48,345,573
10 Day Avg. Volume1,652,878
30 Day Avg. Volume1,107,267
Standard Deviation0.35
R-Squared0.02
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.26
Price to Sales (P/S)2.64
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.25
Forecast
1Y Price Target
$5.00Price Target Upside728.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
BioAtla News
PremiumCompany Announcements
BioAtla Secures $9.2M for Clinical Program Advancements
PremiumCompany Announcements
BioAtla Highlights Advancements in CAB Cancer Therapy
PremiumCompany Announcements
BioAtla Reports Q3 2024 Financial Results and Clinical Advances
Bulls Say, Bears Say
Bulls Say
Promising Clinical ResultsBioAtla achieved promising results in HNSCC with ozuriftamab vedotin, showing a 38% overall response rate, including one confirmed complete response.
Regulatory SupportThe FDA has shown support for a pivotal trial in HNSCC for BioAtla's ozuriftamab vedotin, which could potentially lead to accelerated approval.
Strategic PartnershipsThere is a potential partnership on the horizon for BioAtla, which could positively impact the company's future.
Bears Say
Financial PerformanceBioAtla's financial results for 3Q24 reported a net loss, with R&D expenses exceeding estimates.
Pipeline And Development IssuesThe development of mecbotamab vedotin (BA3011) for both undifferentiated pleomorphic sarcoma and non-small cell lung cancer indications has stalled.
Regulatory ChallengesThe FDA recommended further dose optimization for both BA3021 and BA3071 before initiating potentially registrational studies.
---
Ownership Overview
7.93% Insiders
5.03% Mutual Funds
0.80% Other Institutional Investors
81.34% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCAB FAQ
What was BioAtla’s price range in the past 12 months?
BioAtla lowest stock price was $0.57 and its highest was $4.02 in the past 12 months.
What is BioAtla’s market cap?
Currently, no data Available
When is BioAtla’s upcoming earnings report date?
BioAtla’s upcoming earnings report date is Mar 20, 2025 which is in 71 days.
How were BioAtla’s earnings last quarter?
BioAtla released its earnings results on Nov 07, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.413 by $0.193.
Is BioAtla overvalued?
According to Wall Street analysts BioAtla’s price is currently Undervalued.
Does BioAtla pay dividends?
BioAtla does not currently pay dividends.
What is BioAtla’s EPS estimate?
BioAtla’s EPS estimate is -$0.39.
How many shares outstanding does BioAtla have?
BioAtla has 58,024,730 shares outstanding.
What happened to BioAtla’s price movement after its last earnings report?
BioAtla reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.413. Following the earnings report the stock price went down -5.405%.
Which hedge fund is a major shareholder of BioAtla?
Among the largest hedge funds holding BioAtla’s share is Scion Asset Management. It holds BioAtla’s shares valued at N/A.
---
BioAtla Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (728.50% Upside)
$5.00 (728.50% Upside)
Blogger Sentiment
Bullish
BCAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 634.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 11.9%
Last 30 Days ▼ 11.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.74%
12-Months-Change
Fundamentals
Return on Equity
-139.06%
Trailing 12-Months
Asset Growth
-58.88%
Trailing 12-Months
Company Description
BioAtla
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
---
BCAB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call indicates significant progress in clinical trials and strategic collaborations, with promising results in key oncology programs and financial improvements. However, there are challenges in maintaining R&D spending and managing cash reserves.Read More>---
BCAB Stock 12 Month Forecast
Average Price Target
$5.00
▲(728.50% Upside)
Technical Analysis
Best Analysts Covering BCAB
1 Year
1 Year Success Rate
3/18 ratings generated profit
1 Year Average Return
-46.06%
reiterated a buy rating 2 months ago
Copying Reni Benjamin's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -46.06% per trade.
---